0001209191-20-058830.txt : 20201117 0001209191-20-058830.hdr.sgml : 20201117 20201117173930 ACCESSION NUMBER: 0001209191-20-058830 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201116 FILED AS OF DATE: 20201117 DATE AS OF CHANGE: 20201117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brege Laura CENTRAL INDEX KEY: 0001365619 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 201322207 MAIL ADDRESS: STREET 1: C/O ONYX PHARMACEUTICALS, INC. STREET 2: 2100 POWELL STREET CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-16 0 0001396814 Pacira BioSciences, Inc. PCRX 0001365619 Brege Laura C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 1 0 0 0 Common Stock 2020-11-16 4 M 0 12000 13.98 A 19921 D Common Stock 2020-11-16 4 S 0 12000 65.95 D 7921 D Stock Option (Right to Buy) 13.98 2020-11-16 4 M 0 12000 0.00 D 2021-06-02 Common Stock 12000 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.930 to $66.015, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested and became exercisable in 24 equal monthly installments beginning on July 2, 2011. /s/ Kristen Williams, Attorney-in-Fact 2020-11-17